Concord Wealth Partners Intellia Therapeutics, Inc. Transaction History

Concord Wealth Partners

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 27, 2023	BUY	$33.21 - $62.69 $99 - $188	3 New	3 $0
Q2 2022 Aug 04, 2022	SELL	$38.49 - $76.21 $53,924 - $106,770	-1,401 Reduced 79.29%	366 $19,000
Q1 2022 Apr 20, 2022	SELL	$58.27 - $118.99 $1,398 - $2,855	-24 Reduced 1.34%	1,767 $128,000
Q4 2021 Jan 21, 2022	BUY	$100.76 - $138.36 $133,204 - $182,911	1,322 Added 281.88%	1,791 $212,000
Q3 2021 Nov 09, 2021	SELL	$132.37 - $176.78 $145,739 - $194,634	-1,101 Reduced 70.13%	469 $63,000
Q2 2021 Jul 29, 2021	BUY	$60.88 - $161.91 $14,672 - $39,020	241 Added 18.13%	1,570 $254,000
Q1 2021 May 13, 2021	BUY	$46.59 - $83.68 $59,728 - $107,277	1,282 Added 2727.66%	1,329 $107,000
Q4 2020 Feb 16, 2021	BUY	$18.83 - $63.53 $885 - $2,985	47 New	47 $3,000

336

96.1M

1.06M

863K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $707M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

Stay updated on Concord Wealth Partners with notifications on news.